A Phase II, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain or Leptomeningeal Metastases
Latest Information Update: 05 Feb 2024
At a glance
- Drugs TY 9591 (Primary)
- Indications Brain metastases; Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors TYK Medicine
- 28 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 14 May 2022 Status changed from not yet recruiting to recruiting.
- 08 Dec 2021 New trial record